Femasys: 24% pregnancy rate with FemaSeed in severe male factor infertility trial, more than triple IUI rate

FEMASYS INC

Pivotal trial: 24% of women became pregnant after FemaSeed in severe male factor (TMSC 1M-20M), vs 6.7% per cycle for IUI in literature.
Majority of successful pregnancies required only one FemaSeed procedure.
No new safety concerns; adverse events mild and consistent with known IUI events.
FDA clearance obtained September 2023; commercial launch planned first half of 2024.
Capital infusion at end of 2023 provides funding into second half of 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.